Objective: This study aimed to determine if the antioxidant N-acetylcysteine (NAC) is able to alter peripheral and central redox capabilities in patients with Parkinson disease (PD) or Gaucher disease (GD).
D ecreased nigral glutathione (GSH) in Parkinson disease 1 (PD) and increased reactive oxygen species in blood and skin fibroblasts in Gaucher disease 2, 3 (GD) support the presence of oxidative stress in PD and GD. This study was undertaken to determine if the antioxidant N-acetylcysteine (NAC) is able to alter peripheral and central redox capabilities in these patients. We show for the first time that a single intravenous dose of NAC increases whole blood GSH redox ratio (GSH/GSSG) in PD, GD, and healthy controls (HC), which is then followed by an increase in brain [GSH] as measured by 7-T magnetic resonance spectroscopy (MRS).
Multiple pathogenic factors including oxidative stress, mitochondrial dysfunction, lysosomal or proteasomal dysfunction, and GSH depletion are thought to contribute to the pathogenesis of PD. [4] [5] [6] [7] The significance of GSH depletion is not established; however, a reduction in GSH or alteration in GSH redox status may occur early in PD progression and could be a result of oxidative stress. 7 Gaucher disease is a lysosomal disorder that is caused by deficient glucocerebrosidase (GBA) enzyme activity. A connection has been made between GD and PD, as those with homozygous and heterozygous mutations of GBA are at greater risk for developing PD. 8 Altered GBA enzyme activity appears to contribute to increased α-synuclein misfolding and aggregation, which may also be enhanced by altered redox status within neurons. 9 Because GSH depletion in PD and an impaired adaptive response to oxidative stress in GD have both been observed, antioxidants that increase GSH may have a protective effect in these disorders. Unfortunately, past PD research using intravenously administered GSH failed to provide a definitive benefit. 10 This failure may be related to a suboptimal dosing regimen but more likely is due to the saturable mechanism for GSH passage across the blood-brain barrier as well as a lack of uptake into neurons. [11] [12] [13] A possible way to boost central nervous system GSH levels while avoiding the aforementioned is to use NAC, a membranepermeable cysteine precursor that serves as the rate-limiting substrate for GSH biosynthesis. N-acetylcysteine increases intracellular GSH in human erythrocytes 14 ; however, its effect on human brain GSH concentrations is unknown. Despite in vivo studies of NAC in animal models of neurodegenerative disease 15, 16 and a small clinical trial of oral NAC in patients with late-stage Alzheimer disease, 17 it has yet to be shown that NAC can in fact alter GSH concentrations in the human brain. We hypothesized that intravenously administered NAC increases brain GSH concentrations and blood GSH/GSSG ratios. We used ultrahigh field MRS methodology 18 to measure the effect of NAC administration on cerebral GSH levels and mass spectrometry to measure its effects on blood redox status.
METHODS

Subjects
This study enrolled 3 people with PD, 3 people with GD, and 3 HCs. The study protocol was approved by the University 
Clinical Assessments and Study Scheme
Age, ethnicity, sex, disease duration, weight, smoking status, use of alcohol and illicit drugs, Unified Parkinson Disease Rating Scale score (I-III), Hoehn and Yahr staging, Montreal Cognitive Assessment Score, medications, supplements, and vital signs were recorded at baseline. After collection of a baseline blood sample, the subject was placed into the magnetic resonance scanner to determine the baseline brain GSH concentration. The subject was then removed from the scanner, and NAC (150 mg/kg) was administered intravenously over 1 hour. The subject was placed back into the scanner approximately 30 minutes after the start of infusion, and brain GSH measurements and blood samples were collected at 15-minute intervals until 1 hour after the end of the infusion.
Magnetic Resonance Spectroscopy Protocol
Brain magnetic resonance scans were performed using a 7-T, 90-cm horizontal bore magnet (Siemens MAGNETOM, Erlangen, Germany) and a quadrature surface coil, as described previously. 18 Images acquired with a 2 × 1 × 2-mm resolution magnetization prepared rapid acquisition gradient echo sequence were used for the selection of the volume of interest (VOI). All firstand second-order shims were adjusted using FASTMAP with echo-planar imaging readout. 19 Spectra were acquired from the occipital cortex (22 × 22 × 22 mm 3 ) with a modified semi-LASER sequence (echo time [TE] = 26 milliseconds; repetition time [TR] = 5 seconds). 20 Unsuppressed water spectra acquired from the same VOI were used to remove residual eddy current effects and as a quantification reference. Single-shot data were saved during acquisition; individual free induction decay were frequency and phase corrected before summation.
Metabolite Quantification
Metabolites were quantified using LCModel 21 as described before. 18, 20 The metabolite model spectra were generated based on previously reported chemical shifts and coupling constants. 22, 23 Macromolecule spectra were acquired from the occipital cortex using an inversion recovery sequence (TR = 2 seconds, inversion time [TI] = 0.680 seconds). 24 Metabolites quantified with Cramér-Rao lower bounds (estimated error of the metabolite quantification) greater than 50% or correlation coefficient less than −0.5 were classified as not detected. 25 Concentrations were not corrected for T 1 and T 2 effects or cerebrospinal fluid contribution to the VOI.
GSH/GSSG Redox Ratio
Sample Collection and Analysis
Blood samples were collected via a catheter that was placed in the subject's lower leg into a tube containing EDTA. To prevent GSH oxidation, 1 mL of whole blood was immediately mixed with 0.5 mL of 3% metaphosphoric acid (Sigma [Sigma-Aldrich, St Louis,Mo]). The blood samples were stored at 4°C and analyzed the same day as blood collection. Fifty microliters of blood were extracted with 2 mL of methanol (Fisher [Fisher Scientific, Fair Lawn, NJ]). The supernatant was evaporated and reconstituted in 300 μL of mobile phase and filtered into highperformance liquid chromatography vials using Acrodisc nylon syringe filters (Pall Corporation, Ann Arbor, Mich). The chromatographic system used consisted of a Hewlett-Packard 1100 series (Agilent Technologies, Santa Clara, Calif) with a quadrupole mass spectrometer (model G1946A). The analytes were separated using a Zorbax Eclipse (Agilent Technologies) XDB C18 column (150 × 3.0 mm, 3.5-μ particle size) and eluted isocratically with a mobile phase consisting of 20 mM ammonium formate (Fluka, Steinheim, Germany) buffer (pH 3.5) and acetonitrile (Sigma; 98:2 vol/vol). The analytes were detected using an electrospray ionization-mass spectrometry system in the positive ion mode (quantitation ions:m/z 122, m/z 164, m/z 308, and m/z 613 for cysteine, NAC, GSH, and oxidized GSH [GSSG], respectively). Each sample was analyzed in triplicate. The GSH/GSSG redox ratio was determined using the peak area response ratio for GSH and GSSG. GSH/GSSG redox ratio was reported as the mean of the triplicate values with all values within 50% of the mean.
Data Analysis
Percent change from baseline was calculated for both blood GSH/GSSG ratios and brain GSH levels for each subject at each time point. Maximal percent change for each subject was determined.
RESULTS
Blood GSH/GSSG ratios increased after the start of NAC infusion, reaching a maximum at approximately 60 to 75 minutes. Brain [GSH] also increased with maximal values observed at approximately 90 to 110 minutes after the start of infusion. Subjects with the greatest percent change in blood GSH/GSSG ratio after NAC infusion also had the greatest percent change in brain [GSH], with the exception of subject PD03 (Fig. 1) . The mean maximal percent change from baseline in brain [GSH] was 55%, 41%, and 34% in the PD, GD, and HC groups, respectively. Although brain [GSH] reached maximal percent change from baseline at 90 to 110 minutes and then began to decline in all subjects, none of the subjects had returned to their baseline brain [GSH] at 120 minutes after NAC infusion.
DISCUSSION
In this proof-of-concept study, we show that brain GSH levels and blood GSH redox ratios increase after intravenous NAC administration and thereby demonstrate the feasibility of altering and monitoring changes in peripheral and central antioxidant status. These results support the hypothesis that NAC enhances GSH synthesis in the brain. Although the ultimate question as to whether altering brain [GSH] will affect the course of PD or GD remains unanswered, this represents the first demonstration that MRS can measure pharmacodynamic changes in response to intravenous NAC administration in PD, GD, and controls. The [GSH] measured by MRS in the occipital cortex VOI also includes the contribution of blood GSH. However, blood makes up only approximately 3% of the volume in the brain. 26 Thus, the change detected in brain [GSH] in this study could not be due primarily to the contribution of blood GSH because the mean maximal increase in blood GSH of 30% measured in this study would only lead to an MRS voxel [GSH] increase of 0.9%. In addition, the maximal change in the brain [GSH] occurred with a approximately 30 minutes delay relative to the redox change in blood ( Fig. 1) , further substantiating the limited effect of blood on the brain measurement.
Although the mean maximal percent change from baseline in brain GSH appeared to differ among the subject groups, the number of subjects in this study is too small to draw any definitive conclusions. A study involving a larger number of subjects is required to determine if individuals with PD or GD have altered baseline GSH levels that may be due to their subtype or severity of condition, for example, cortical Lewy pathology in advanced PD, and whether there are differences in the change from baseline in brain [GSH] between subject types. In this study, we focused on the occipital cortex rather than the substantia nigra, where a GSH deficit has been detected postmortem in PD. 1 Because of challenges associated with MRS in the substantia nigra in humans, including its location, very small size (limiting signal-to-noise ratio), and high iron content (giving rise to broad intrinsic line widths, thereby limiting spectral resolution), 27, 28 we chose the occipital cortex to increase our chances of reliably detecting a NAC effect on [GSH]. Our results suggest that the effect of NAC on [GSH] is global and that NAC is able to increase brain [GSH] even in controls.
After a single intravenous NAC dose, we observed a transient increase in blood GSH redox ratio, which was attributed to an increase in GSH and a decrease in GSSG in all subjects. GSSG disassociation by NAC, resulting in a NAC-GS complex and free GSH, could contribute to the transient nature of this change. Despite a rapid decrease in whole blood GSH redox ratios after the end of the NAC infusion, [GSH] in the brain remained elevated at 2 hours after the start of infusion. It is unknown whether the pharmacologic actions of NAC will be the same for oral administration.
There are reports of positive effects of oral NAC in disorders with central nervous system involvement. 29, 30 Future studies are necessary to determine if oral NAC affects brain [GSH] and if so, to establish optimal dosage regimens to attain sustained elevation of brain [GSH] with repeated dosing.
